紫鑫藥業(002118.SZ)與國藥兆祥簽署原材料購銷協議 2021年採購金額達3億元
格隆匯4月20日丨紫鑫藥業(002118.SZ)宣佈,2021年4月20日,公司作為甲方與國藥兆祥(長春)醫藥有限公司(簡稱“國藥兆祥”)作為乙方簽署了《原材料購銷協議書》。經甲乙雙方共同協商,甲方向乙方採購2021年度總金額為3億元的原材料,具體採購品種及數量以雙方簽訂的“購貨合同”為準。
國藥兆祥是國藥藥材股份有限公司下屬公司,依託國藥平台致力於中藥領域的種植、生產與批發,構建了縱向一體化的中藥產業鏈。國藥兆祥本部從事大宗常用中藥材經營、中藥材進出口業務、中藥材種植、中成藥生產,形成了藥材貿易、代理業務、中成藥生產三足鼎立協調發展的業務格局。在河北安國、安徽亳州等地有多家上游藥材供應公司,採購的藥材主要銷售給國藥藥材股份有限公司等大型國有藥材企業,建立了遍及全國各地的營銷網絡,是中國最大、最可信賴的中藥原料藥供應商之一。
公司表示,該協議的簽訂符合公司發展戰略和經營計劃,有利於保障公司原材料的長期穩定供應。協議中分期分額採購,有利於降低公司供應鏈成本併為公司原材料的成本競爭優勢提供支撐,同時購銷貨款期限為四個月,可以緩解公司生產經營資金週轉緊張問題。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.